DS-5573a
DS-5573a is a human monoclonal antibody targeting B7-H3, with a Kd of 1.8 nM for the 4Ig isoform and 11 nM for the 2Ig isoform. DS-5573a induces antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis against B7-H3-expressing cancer cells. DS-5573a exerts dose-dependent anti-tumor activity via effector cells. DS-5573a can be used in the research of cancers including breast adenocarcinoma, non-small cell lung cancer, renal cell adenocarcinoma, gastric cancer and prostate cancer.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Human
|
4IgB7-H3 1.8 nM (Kd) |
2IgB7-H3 11 nM (Kd) |
DS-5573a (1 μg/mL) binds to the IgC1 and IgC2 domains of human B7-H3 expressed in transfected CHO-K1 cells[1].
The Kd value of DS-5573a binding to recombinant human 4IgB7-H3 is 1.8 nM, and the Kd value of its binding to recombinant human 2IgB7-H3 is 11 nM[1].
DS-5573a (0.01-1000 ng/mL; 4 h) exerts potent, B7-H3-dependent antibody-dependent cell-mediated cytotoxicity against NCI-H322, MDA-MB-231 and COLO205 cells via human peripheral blood mononuclear cells (PBMC), while exhibits only minimal activity against B7-H3-negative CCRF-CEM cells[1].
DS-5573a (1-10000 ng/mL; 3 h) exerts B7-H3-dependent antibody-dependent cellular phagocytosis (ADCP) activity against NCI-H322, MDA-MB-231 and COLO205 cells via human monocyte-derived macrophages, but shows no activity against B7-H3-negative CCRF-CEM cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:NCI-H322, MDA-MB-231, and COLO205 cells
-
Concentration:0.01, 0.1, 1, 10, 100, 1000 ng/mL
-
Incubation Time:4 h
-
Result:Exerted potent, B7-H3-dependent ADCC activity against NCI-H322, MDA-MB-231, and COLO205 cells via human PBMCs.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CB17/Icr-Prkdcscid/CrlCrlj (female, breast adenocarcinoma model via s.c. inoculation of 5×106 MDA-MB-231 cells in Matrigel into right flank)[1]
-
Dosage:0.003 mg/kg; 0.03 mg/kg; 0.3 mg/kg; 3 mg/kg
-
Administration:i.p.; once a week; 5 weeks
-
Result:Exhibited dose-dependent and statistically significant antitumor efficacy compared with vehicle-treated group: 0.03 mg/kg, 0.3 mg/kg, 3 mg/kg.
Reduced estimated tumor volumes in all treated groups relative to vehicle at 7 days after final treatment, with greatest reduction seen at 0.3 mg/kg and 3 mg/kg doses.
B7-H3/CD276
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
DS-5573a Related Classifications
HY-P992347 Related Classifications
Powered by Bioz